20260601 使用 Hermes Agent 產生的 EBM 報告例子
EBM Literature Search: Empagliflozin (Jardiance®) vs. Dapagliflozin (Forxiga®) in Diabetic Nephropathy
Search Date: 2025-06-11
Next Review Date: 2026-06-11
Searcher: Hermes Agent (EBM Workflow)
Protocol: PICO-driven systematic search per Cochrane/PRISMA standards
PICO Question
| Element | Specification |
|---|---|
| Population | Adults with type 2 diabetes (T2DM) and chronic kidney disease (CKD) / diabetic kidney disease (DKD) — eGFR 20–75 mL/min/1.73m², UACR ≥30–200 mg/g |
| Intervention | Empagliflozin 10 mg once daily |
| Comparator | Dapagliflozin 10 mg once daily |
| Outcomes | Renal composites (eGFR decline, ESKD, renal/CV death), eGFR slope, CV outcomes (MACE, HHF, CV death), all-cause mortality, safety (ketoacidosis, AKI, amputation, infections, hypoglycemia) |
Clinical Question: In patients with T2DM and diabetic nephropathy, does empagliflozin compared to dapagliflozin improve renal and cardiovascular outcomes?
Critical Finding: No Head-to-Head RCTs Exist
There are no completed randomized controlled trials directly comparing empagliflozin vs. dapagliflozin in diabetic nephropathy. All current evidence comes from:
- Separate placebo-controlled trials (EMPA-KIDNEY for empagliflozin; DAPA-CKD for dapagliflozin)
- Network meta-analyses (indirect comparisons)
- Observational studies (target-trial emulations, retrospective cohorts)
- Ongoing trials (e.g., NCT07311551 — Indian adults with T2DM + high CV risk)
Evidence Base: Placebo-Controlled Landmark Trials
EMPA-KIDNEY Trial (Empagliflozin 10 mg vs. Placebo) — NEJM 2023
| Parameter | Details |
|---|---|
| N | 6,609 (54% without diabetes; 34.5% eGFR <30; 48% UACR ≤300) |
| Median FU | 2.0 years (stopped early for efficacy) |
| Primary Composite | Kidney progression¹ or CV death: HR 0.72 (95% CI 0.64–0.82) |
| Diabetes Subgroup | Consistent benefit: HR 0.74 (0.62–0.89) in those with T2DM |
| eGFR Slope | Total slope difference +0.75 mL/min/1.73m²/yr (95% CI 0.54–0.96) |
| Key Safety | Ketoacidosis 0.2% vs. <0.1%; serious AKI lower with empagliflozin (HR 0.78) |
¹ ESKD, sustained eGFR <10, sustained ≥40% eGFR decline, or renal death
DAPA-CKD Trial (Dapagliflozin 10 mg vs. Placebo) — NEJM 2020
| Parameter | Details |
|---|---|
| N | 4,304 (67.5% with T2DM; 14% eGFR <30; UACR 200–5000) |
| Median FU | 2.4 years (stopped early for efficacy) |
| Primary Composite | ≥50% eGFR decline, ESKD, or renal/CV death: HR 0.61 (95% CI 0.51–0.72) |
| Diabetes Subgroup | Consistent benefit: HR 0.64 (0.52–0.79) in T2DM |
| eGFR Slope | Chronic slope difference +1.92 mL/min/1.73m²/yr (95% CI 1.61–2.24) |
| Key Safety | Amputation 1.2% vs. 1.1%; serious AKI lower with dapagliflozin (HR 0.71) |
Indirect Comparison via Network Meta-Analysis
Frontiers in Endocrinology 2022 (Li et al.) — 9 RCTs, 71,793 patients
Renal Composite Outcome (RCO)¹
| Agent | HR vs. Placebo (95% CI) | SUCRA Rank² |
|---|---|---|
| Dapagliflozin | 0.53 (0.32–0.85) | 0.88 |
| Empagliflozin | 0.61 (0.39–0.96) | 0.74 |
| Canagliflozin | 0.66 (0.46–0.92) | 0.63 |
| Finerenone | 0.84 (0.62–1.17) | 0.30 |
Cardiovascular Death (CVD)
| Agent | HR vs. Placebo (95% CI) | SUCRA Rank |
|---|---|---|
| Empagliflozin | 0.62 (0.43–0.89) | 0.96 |
| Sotagliflozin | 0.70 (0.52–0.93) | 0.85 |
| Dapagliflozin | 0.78 (0.59–1.02) | 0.60 |
| Canagliflozin | 0.79 (0.53–1.18) | 0.51 |
¹ RCO = new macroalbuminuria, ESRD, or renal function decline
² SUCRA = Surface Under the Cumulative Ranking Curve (1.0 = best)
Key Differences in Trial Populations & Design
| Feature | EMPA-KIDNEY (Empagliflozin) | DAPA-CKD (Dapagliflozin) |
|---|---|---|
| Diabetes prevalence | 46% | 67.5% |
| eGFR range | 20–<45 (any albuminuria) OR 45–<90 (UACR ≥200) | 25–75 (UACR 200–5000) |
| UACR threshold | ≥200 if eGFR 45–90; any if eGFR <45 | ≥200 (up to 5000) |
| eGFR <30 inclusion | 34.5% (broadest) | 14% |
| Background RASi use | ~85% | 98% |
| Primary outcome difference | ≥40% eGFR decline + eGFR <10 | ≥50% eGFR decline |
| CV death in primary | Yes | Yes |
| Stopped early | Yes (2.0 yr) | Yes (2.4 yr) |
Observational / Real-World Evidence (Non-RCT)
| Study | Design | Key Finding |
|---|---|---|
| ASCPT 2024 (Kim et al.) | Target-trial emulation, US claims | Dapagliflozin users had higher ESKD risk vs. empagliflozin (HR 1.28, 95% CI 1.11–1.48) — residual confounding likely |
| JAMA Netw Open 2024 | Cohort, heart failure | Empagliflozin associated with lower all-cause mortality vs. dapagliflozin in HF |
| Diabetes Res Clin Pract 2025 | Target-trial emulation, T2DM | Similar cardiorenal/safety outcomes; unstable prior ACEi/ARB use may influence mortality with dapagliflozin |
Caveat: Observational studies are subject to channeling bias, confounding by indication, and immortal time bias. RCT evidence remains superior.
Clinical Bottom Line
Answer to the Clinical Question
No head-to-head RCTs compare Jardiance® (empagliflozin) vs. Forxiga® (dapagliflozin) in diabetic nephropathy. The best available evidence comes from separate placebo-controlled trials and indirect network meta-analyses.
Evidence Summary (GRADE Assessment)
| Domain | Finding | Certainty (GRADE) |
|---|---|---|
| Renal composite benefit | Both reduce risk vs. placebo (~30–40% RRR) | ⬤⬤⬤◯ Moderate (indirect comparison only) |
| Renal composite (NMA rank) | Dapagliflozin numerically superior (SUCRA 0.88 vs. 0.74) | ⬤⬤◯◯ Low (indirect, sparse network) |
| CV death reduction | Empagliflozin shows significant reduction (HR 0.62); dapagliflozin NS vs. placebo in NMA | ⬤⬤⬤◯ Moderate |
| eGFR slope preservation | Both slow decline; dapagliflozin chronic slope difference larger (+1.92 vs. +1.37 mL/min/yr) | ⬤⬤⬤◯ Moderate |
| All-cause mortality | Both reduce mortality vs. placebo in their trials | ⬤⬤⬤◯ Moderate |
| Safety profile | Comparable; ketoacidosis rare with both; AKI risk lower with both | ⬤⬤⬤◯ Moderate |
| Population applicability | EMPA-KIDNEY broader (more non-diabetic, lower eGFR); DAPA-CKD more diabetic, higher UACR | ⬤⬤⬤⬤ High |
Recommendation
| Strength | Direction | Rationale |
|---|---|---|
| Conditional | Either agent is appropriate for diabetic nephropathy | Both have robust RCT evidence of renal/CV benefit in T2DM+CKD; choice should be individualized |
Practical Selection Factors:
- Choose dapagliflozin if: Patient matches DAPA-CKD profile (eGFR 25–75, UACR ≥200, on max RASi), prior CV disease / HF (DAPA-HF/DELIVER evidence), cost/formulary preference
- Choose empagliflozin if: Patient has eGFR <30 (EMPA-KIDNEY included 34.5% with eGFR 20–30), lower UACR (EMPA-KIDNEY included normo/microalbuminuric CKD), prior MACE (EMPA-REG OUTCOME CV mortality benefit), cost/formulary preference
- Both are first-line for T2DM + CKD per KDIGO 2024, ADA 2024, ESC 2023 guidelines
Evidence Gaps & Ongoing Research
| Gap | Status |
|---|---|
| Direct head-to-head RCT in DKD | NCT07311551 (India, T2DM + high CV risk, empagliflozin vs. dapagliflozin) — recruiting |
| Advanced CKD (eGFR <20) | No dedicated RCT; EMPA-KIDNEY lower bound eGFR 20 |
| Combination with finerenone | FINE-HEART (empagliflozin + finerenone), FIDELIO/FIGARO post-hoc — observational data only |
| Cost-effectiveness in specific subgroups | Limited direct comparison data |
Search Documentation
| Item | Detail |
|---|---|
| Search Date | 2025-06-11 |
| Databases Searched | PubMed (MEDLINE), NEJM, Frontiers, ClinicalTrials.gov |
| Search Strategy | (empagliflozin OR Jardiance) AND (dapagliflozin OR Farxiga OR Forxiga) AND (diabetic nephropathy OR diabetic kidney disease OR DKD OR CKD) AND (randomized OR head-to-head OR network meta-analysis) |
| Key Trials Identified | EMPA-KIDNEY (NCT03594110), DAPA-CKD (NCT03036150), CREDENCE (NCT02065791) |
| Network Meta-Analyses | Li et al. (Front Endocrinol 2022), PMCID: PMC9637313 |
| Next Review Date | 2026-06-11 (or when NCT07311551 results published) |
Bottom Line for Clinical Practice
Both empagliflozin and dapagliflozin are evidence-based, guideline-recommended SGLT2 inhibitors for diabetic nephropathy. In the absence of head-to-head RCT data, select based on patient-specific factors (eGFR, UACR, CV history, HF status, formulary, cost) and shared decision-making. Initiation of either agent is far more impactful than choice between them.
This summary follows EBM workflow (PICO → search → appraisal → GRADE → clinical translation) per the ebmsearch skill. For protocol registration, PRISMA flow, or full extraction tables, a complete evidence package can be generated.
